Introduction

Chediak-Higashi Syndrome (CHS) is a rare genetic disorder initiated by a mutation in a single gene, LYST.¹ As an "autosomal recessive" disease, a child inherits a defective copy from both parents to be affected.² This gene supplies the template for one such controller protein that regulates material traffic inside our cells.

If this protein malfunctions, cellular cargo units, known as granules, fuse and become hugely enlarged and dysfunctional—a microscopic indication that's characteristic of the disease.¹

This cellular chaos manifests as a unique combination of symptoms:

• Reduced pigment within the hair, eyes, and epidermis (partial albinism)
• A mild bleeding tendency
• A significantly compromised immunity that experiences repeated infections

From accelerated phase to HLH

For about 85% of individuals with CHS, the chronic illness suddenly gives way to a catastrophic event.³ For decades, this was simply called the "accelerated phase," a term that conveyed urgency but revealed little about the underlying biology. We now know this crisis is a specific syndrome: Hemophagocytic Lymphohistiocytosis (HLH).

This isn't just an infection; it's an absolute loss of immune control. The immune system's "off-switch" is faulty, causing a runaway inflammation called a "cytokine storm" that targets the body's own organs. This inside attack results in sustained high fevers, liver and spleen that are seriously swollen, and bone marrow destruction with wholesale devastation of blood cells.²

But what makes HLH particularly deadly is its insidious presentation. Early, the pattern of fever, low blood counts, and enlarged organs can be nearly indistinguishable from life-threatening sepsis. This diagnostic nightmare, unfortunately, can delay the initiation of life-saving therapy.

What is immunosuppressive therapy?

Once a patient with CHS progresses into the life-threatening HLH category, the purpose of therapy shifts from addressing chronic symptoms to stopping an overactive immune system that is dangerously out of control. To accomplish this, doctors turn to a powerful class of medications for an immunosuppressive therapy regimen.

Introduction to immunosuppressive therapy

Immunosuppressive therapy is a treatment that uses medications to deliberately lower, or "suppress," the activity of the body's immune system.⁴ It is a common approach for conditions where the immune system mistakenly attacks healthy cells, such as in autoimmune diseases, or to prevent the body from rejecting a transplanted organ.

The role of immunosuppressive therapy in CHS

In the context of CHS, the primary role of immunosuppressive therapy, which includes chemotherapy and steroids, is to halt the hyperinflammatory state urgently. It is not a cure for the underlying genetic defect of CHS, but it is an essential emergency measure to stabilise the patient and prevent imminent death from organ damage.

Current treatment and limitations

Standardised treatment: The HLH protocols

The treatment for the accelerated phase (HLH) follows standardised international protocols, with the HLH-94 and HLH-2004 regimens being the most widely used.⁵ These protocols have significantly improved survival rates and utilise a combination of powerful drugs to suppress the overactive immune system.

The core components include:

• Corticosteroids (e.g., Dexamethasone): These powerful anti-inflammatory drugs are used to reduce systemic inflammation and control the cytokine storm quickly
• Chemotherapy (e.g., Etoposide): The medication is part of the regimen, designed to eliminate the massively overactivated immune cells (T-cells and macrophages) that are causing hyperinflammation and organ destruction
• Other Immunosuppressants (e.g., Cyclosporine A): The HLH-2004 protocol added cyclosporine at the initiation of treatment to achieve broader and earlier immunosuppression

A bridge to a definitive cure

It is essential to understand that immunosuppressive therapy is not a permanent cure for CHS. The literature consistently frames this intervention as a crucial "bridge to transplant". The goal is to induce a temporary remission of the HLH, thereby stabilising the patient's condition so they can safely undergo the only definitive, curative treatment for the hematologic and immunologic aspects of the disease: allogeneic hematopoietic stem cell transplantation (HSCT), also known as a bone marrow transplant.⁶

Attempting an HSCT during an active HLH crisis is associated with a much higher rate of mortality.⁷ Therefore, the initial chemo-immunotherapy is designed to control the hyperinflammation, allowing the patient to reach transplantation in a state of remission, which significantly improves the chances of a successful outcome. 

Case examples in clinical practice

One report describes the experience of a 5-month-old girl diagnosed with HLH after presentation with fever based on composite clinical signs and laboratory markers, such as evidence of hemophagocytosis on her bone marrow examination.⁴ She was immediately treated with the HLH-2004 protocol with etoposide and dexamethasone. After this initial 8-week treatment, her disease entered remission, showing the protocol's success with managing the short-term crisis while enabling continuation therapy with plans for eventual stem cell transplant.

However, the entire treatment pathway has a major limitation: neither the primary immunosuppressive regimen nor the follow-up HSCT prevents or reverses progressive neurological impairment that is part of CHS. Patients recuperating successfully and surviving into adolescence and adulthood continue to develop serious neurological issues, a core unsolved issue with long-term disease management.

The limits of the treatment

An HSCT can be life-saving. By replacing the patient's faulty bone marrow with a healthy donor's, it permanently corrects the immune defect and eliminates the risk of HLH recurring. However, calling hematopoietic stem cell transplantation (HSCT) of Chediak-Higashi Syndrome (CHS) a "cure" is an oversimplification that has the potential for the outcome.

Although HSCT achieves the exchange of the abnormal hematopoietic and immune systems, it neither treats nor prevents the underlying pathophysiology of the nervous system, with the LYST mutation continuing to afflict neurally located cells. Accordingly, evidence from several reviews demonstrates that HSCT prevents neither progressive neurological decline, seen in most patients surviving adolescence/adulthood, presenting with motor impairment, deterioration of intellect, and ataxia.

This practical reality serves to illustrate that, even after a seemingly successful transplant, CHS remains a lifelong illness. An understanding of this shortcoming serves the families and caregiving team by reframing HSCT not as a cure, but as an essential step within the context of a life-long management strategy.

FAQs

How do doctors diagnose Chediak-Higashi Syndrome?

Doctors diagnose CHS based on clinical signs like silvery hair, then confirm it with microscopic tests. They look for tell-tale giant granules in white blood cells on a blood smear and clumped pigment in hair shafts. A genetic test for the LYST gene provides the final diagnosis.

Does the type of genetic error affect how sick a person with CHS will be?

Yes, the specific genetic error often predicts the disease's severity. Major errors that stop protein production usually cause the severe, classic childhood form with a high risk of the fatal "accelerated phase". Milder errors may lead to an atypical form with fewer infections but more prominent neurological issues later in life.

A bone marrow transplant can fix the immune problems. What are the long-term challenges?

A bone marrow transplant is a life-saving treatment that fixes the immune problems. However, it does not stop the progressive neurological decline. This can lead to brain tissue shrinkage (atrophy) over time, causing long-term challenges like poor balance, nerve damage, and cognitive issues that typically appear in adolescence or adulthood.

Summary

Chediak-Higashi Syndrome (CHS) is a rare autosomal recessive disease that manifests with immune deficiency, bleeding abnormalities, skin pigment issues, and progressive neurologic deterioration. The most serious and fatal presentation of CHS is the so-called "accelerated phase," which is, in fact, a type of hemophagocytic lymphohistiocytosis (HLH)—a hyperinflammatory syndrome characterised by dysregulated immune activation.

Rather than simply representing the progression of the underlying disease, the accelerated phase represents a separate and life-threatening cytokine storm, in which multiorgan damage results from overactive immune cells. The syndrome has characteristic clinical findings of ongoing fever, hepatosplenomegaly, cytopenias, and elevated inflammatory markers, and, unless treated promptly, is always fatal.

Primary treatment of HLH in CHS comprises immunosuppressive therapy with regimens like HLH-94 or HLH-2004, which generally comprise dexamethasone and etoposide. The purpose of such intervention is neither the cure of the underlying immunodeficiency nor the definitive management of HLH but rather prompt suppression of the hyperinflammatory phenotype and stabilisation of the patient, thus paving the way for definitive therapy.

Despite being the only cure, HSCT does not remedy the neurodegenerative aspect of CHS. Because the transplant does not replace neural tissues, the neurologic symptoms of ataxia, peripheral neuropathy, and cognitive dysfunction typically continue after transplant. Therefore, although successful HSCT results, CHS persists as a chronic, lifelong illness. This necessitates the communication of realistic outcomes with families and making long-term multidisciplinary care plans.